CA2729690A1 - Nouveaux pyrrolo [2,3-a] carbazoles et leur utilisation comme inhibiteurs des kinases pim - Google Patents
Nouveaux pyrrolo [2,3-a] carbazoles et leur utilisation comme inhibiteurs des kinases pim Download PDFInfo
- Publication number
- CA2729690A1 CA2729690A1 CA2729690A CA2729690A CA2729690A1 CA 2729690 A1 CA2729690 A1 CA 2729690A1 CA 2729690 A CA2729690 A CA 2729690A CA 2729690 A CA2729690 A CA 2729690A CA 2729690 A1 CA2729690 A1 CA 2729690A1
- Authority
- CA
- Canada
- Prior art keywords
- dihydropyrrolo
- carbazol
- substituted
- groups
- carbaldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QKYLZESNWDGRJB-UHFFFAOYSA-N pyrrolo[2,3-a]carbazole Chemical class C12=CC=CC=C2N=C2C1=CC=C1C=CN=C12 QKYLZESNWDGRJB-UHFFFAOYSA-N 0.000 title abstract description 5
- 229940043355 kinase inhibitor Drugs 0.000 title description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 152
- -1 sulfophenyl group Chemical group 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 53
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 25
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 22
- 229920006395 saturated elastomer Polymers 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 150000002825 nitriles Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 claims description 15
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims description 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 101100297652 Coturnix japonica PIM3 gene Proteins 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 11
- WRBOHOGDAJPJOQ-UHFFFAOYSA-N 9H-Carbazole-3-carboxaldehyde Chemical compound C1=CC=C2C3=CC(C=O)=CC=C3NC2=C1 WRBOHOGDAJPJOQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000002608 ionic liquid Substances 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 8
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical group NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims description 8
- 229940067157 phenylhydrazine Drugs 0.000 claims description 8
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims description 7
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 7
- PZBQSOWJBOUUIV-UHFFFAOYSA-N 6,8-dichloro-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound C=1C(Cl)=CC(Cl)=C2C=1NC1=C2C=CC2=C1NC=C2C=O PZBQSOWJBOUUIV-UHFFFAOYSA-N 0.000 claims description 7
- JRPUZUBQJFQSQO-UHFFFAOYSA-N 7-bromo-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C12=CC(Br)=CC=C2NC2=C1C=CC1=C2NC=C1 JRPUZUBQJFQSQO-UHFFFAOYSA-N 0.000 claims description 7
- CMILZUZLXJQSGJ-UHFFFAOYSA-N 9-bromo-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound BrC1=CC=CC2=C1NC1=C2C=CC2=C1NC=C2C=O CMILZUZLXJQSGJ-UHFFFAOYSA-N 0.000 claims description 7
- ZRRGYYZOLYHGAW-UHFFFAOYSA-N 9-ethyl-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound CCC1=CC=CC2=C1NC1=C2C=CC2=C1NC=C2C=O ZRRGYYZOLYHGAW-UHFFFAOYSA-N 0.000 claims description 7
- VIRITAWLUCSUIP-UHFFFAOYSA-N 9-fluoro-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound FC1=CC=CC2=C1NC1=C2C=CC2=C1NC=C2C=O VIRITAWLUCSUIP-UHFFFAOYSA-N 0.000 claims description 7
- 125000001118 alkylidene group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 6
- IYKWFKKDLTZONH-UHFFFAOYSA-N 6-bromo-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound C1=2C(Br)=CC=CC=2NC2=C1C=CC1=C2NC=C1C=O IYKWFKKDLTZONH-UHFFFAOYSA-N 0.000 claims description 6
- BFWHRHJPPAUSLJ-UHFFFAOYSA-N 7-(2,4-difluorophenyl)-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound FC1=CC(F)=CC=C1C1=CC=C(NC=2C=3NC=C(C=O)C=3C=CC=22)C2=C1 BFWHRHJPPAUSLJ-UHFFFAOYSA-N 0.000 claims description 6
- MWJXEWYSFDLQRR-UHFFFAOYSA-N 7-fluoro-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound C12=CC(F)=CC=C2NC2=C1C=CC1=C2NC=C1C=O MWJXEWYSFDLQRR-UHFFFAOYSA-N 0.000 claims description 6
- OGEKUJPOQMHESI-UHFFFAOYSA-N 8-methyl-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound C=1C(C)=CC=C2C=1NC1=C2C=CC2=C1NC=C2C=O OGEKUJPOQMHESI-UHFFFAOYSA-N 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- BPHGZSRGCZJRGO-UHFFFAOYSA-N 1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C1=CC=C2NC3=C(NC=C4)C4=CC=C3C2=C1 BPHGZSRGCZJRGO-UHFFFAOYSA-N 0.000 claims description 4
- VWNCOFUKBTYAON-UHFFFAOYSA-N 1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1C=O VWNCOFUKBTYAON-UHFFFAOYSA-N 0.000 claims description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000006919 indolization reaction Methods 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 3
- KUIXBLRMWNOGNN-UHFFFAOYSA-N 7-bromo-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound C12=CC(Br)=CC=C2NC2=C1C=CC1=C2NC=C1C=O KUIXBLRMWNOGNN-UHFFFAOYSA-N 0.000 claims description 3
- MXUOJMMSWVSNGG-UHFFFAOYSA-N 7-phenyl-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound O=CC1=CNC(C=2NC3=CC=4)=C1C=CC=2C3=CC=4C1=CC=CC=C1 MXUOJMMSWVSNGG-UHFFFAOYSA-N 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 150000003857 carboxamides Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- VOSIZKZMNWMHTH-UHFFFAOYSA-N 1,10-dihydropyrrolo[2,3-a]carbazol-3-ylmethanol Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1CO VOSIZKZMNWMHTH-UHFFFAOYSA-N 0.000 claims description 2
- SNKWXCJZGPJMHY-UHFFFAOYSA-N 1,10-dihydropyrrolo[2,3-a]carbazole-7-carbonitrile Chemical compound C12=CC(C#N)=CC=C2NC2=C1C=CC1=C2NC=C1 SNKWXCJZGPJMHY-UHFFFAOYSA-N 0.000 claims description 2
- IPZURMNMOLTFSU-UHFFFAOYSA-N 1-(1,10-dihydropyrrolo[2,3-a]carbazol-3-yl)-2,2,2-trifluoroethanone Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1C(=O)C(F)(F)F IPZURMNMOLTFSU-UHFFFAOYSA-N 0.000 claims description 2
- SQTJPZLGERPVDT-UHFFFAOYSA-N 1-(benzenesulfonyl)-7-bromo-10h-pyrrolo[2,3-a]carbazole Chemical compound C12=CC(Br)=CC=C2NC(C2=3)=C1C=CC=3C=CN2S(=O)(=O)C1=CC=CC=C1 SQTJPZLGERPVDT-UHFFFAOYSA-N 0.000 claims description 2
- LKHSHKRKEPEPKU-UHFFFAOYSA-N 1-[4-(1,10-dihydropyrrolo[2,3-a]carbazol-7-yl)phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=C(NC=2C=3NC=CC=3C=CC=22)C2=C1 LKHSHKRKEPEPKU-UHFFFAOYSA-N 0.000 claims description 2
- NOFRRBJDVTZROX-UHFFFAOYSA-N 2-(1,10-dihydropyrrolo[2,3-a]carbazol-3-yl)-n,n-diethyl-2-oxoacetamide Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1C(=O)C(=O)N(CC)CC NOFRRBJDVTZROX-UHFFFAOYSA-N 0.000 claims description 2
- BFKLLTADWGLXEV-UHFFFAOYSA-N 2-(1,10-dihydropyrrolo[2,3-a]carbazol-3-yl)-n,n-diethylethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1CCN(CC)CC BFKLLTADWGLXEV-UHFFFAOYSA-N 0.000 claims description 2
- KNAUNTGIXRQKQH-UHFFFAOYSA-N 2-(1,10-dihydropyrrolo[2,3-a]carbazol-3-yl)ethanol Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1CCO KNAUNTGIXRQKQH-UHFFFAOYSA-N 0.000 claims description 2
- OETQQPPEDZRIIN-UHFFFAOYSA-N 2-(diethylamino)-1-(1,10-dihydropyrrolo[2,3-a]carbazol-3-yl)ethanol Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1C(O)CN(CC)CC OETQQPPEDZRIIN-UHFFFAOYSA-N 0.000 claims description 2
- HFIDQKQLIDQTPU-UHFFFAOYSA-N 3-formyl-1,10-dihydropyrrolo[2,3-a]carbazole-7-carbonitrile Chemical compound C12=CC(C#N)=CC=C2NC2=C1C=CC1=C2NC=C1C=O HFIDQKQLIDQTPU-UHFFFAOYSA-N 0.000 claims description 2
- AVQHVNUSRJCQBY-UHFFFAOYSA-N 6,8-dichloro-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C=1C(Cl)=CC(Cl)=C2C=1NC1=C2C=CC2=C1NC=C2 AVQHVNUSRJCQBY-UHFFFAOYSA-N 0.000 claims description 2
- XPFWHDMJBYQBFR-UHFFFAOYSA-N 6-bromo-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C1=2C(Br)=CC=CC=2NC2=C1C=CC1=C2NC=C1 XPFWHDMJBYQBFR-UHFFFAOYSA-N 0.000 claims description 2
- CUNJCJHHSCBIHX-UHFFFAOYSA-N 7-(2,4-difluorophenyl)-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound FC1=CC(F)=CC=C1C1=CC=C(NC=2C=3NC=CC=3C=CC=22)C2=C1 CUNJCJHHSCBIHX-UHFFFAOYSA-N 0.000 claims description 2
- WHGSSVUZVLJLCM-UHFFFAOYSA-N 7-(3-methoxyphenyl)-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound COC1=CC=CC(C=2C=C3C4=C(C=5NC=CC=5C=C4)NC3=CC=2)=C1 WHGSSVUZVLJLCM-UHFFFAOYSA-N 0.000 claims description 2
- QATLODFZJKYGRA-UHFFFAOYSA-N 7-(3-methoxyphenyl)-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound COC1=CC=CC(C=2C=C3C4=C(C=5NC=C(C=O)C=5C=C4)NC3=CC=2)=C1 QATLODFZJKYGRA-UHFFFAOYSA-N 0.000 claims description 2
- NMENUZJNIUHBPP-UHFFFAOYSA-N 7-(4-fluorophenyl)-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C1=CC(F)=CC=C1C1=CC=C(NC=2C=3NC=CC=3C=CC=22)C2=C1 NMENUZJNIUHBPP-UHFFFAOYSA-N 0.000 claims description 2
- QLMWVRUUEQQJKG-UHFFFAOYSA-N 7-(4-fluorophenyl)-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound C1=CC(F)=CC=C1C1=CC=C(NC=2C=3NC=C(C=O)C=3C=CC=22)C2=C1 QLMWVRUUEQQJKG-UHFFFAOYSA-N 0.000 claims description 2
- XHTYPHZPQFUXGM-UHFFFAOYSA-N 7-[4-(trifluoromethoxy)phenyl]-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(NC=2C=3NC=CC=3C=CC=22)C2=C1 XHTYPHZPQFUXGM-UHFFFAOYSA-N 0.000 claims description 2
- DJGGSFPUGZBESU-UHFFFAOYSA-N 7-[4-(trifluoromethyl)phenyl]-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=C(NC=2C=3NC=CC=3C=CC=22)C2=C1 DJGGSFPUGZBESU-UHFFFAOYSA-N 0.000 claims description 2
- QPAADJFMYAMJHD-UHFFFAOYSA-N 7-nitro-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC2=C1C=CC1=C2NC=C1 QPAADJFMYAMJHD-UHFFFAOYSA-N 0.000 claims description 2
- UJHXFAONXJTHBT-UHFFFAOYSA-N 7-nitro-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC2=C1C=CC1=C2NC=C1C=O UJHXFAONXJTHBT-UHFFFAOYSA-N 0.000 claims description 2
- CFOKSEVBPFFBCJ-UHFFFAOYSA-N 7-phenyl-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C=1C=C2NC3=C4NC=CC4=CC=C3C2=CC=1C1=CC=CC=C1 CFOKSEVBPFFBCJ-UHFFFAOYSA-N 0.000 claims description 2
- KRUYGAKMSWKQDA-UHFFFAOYSA-N 8-bromo-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C=1C(Br)=CC=C2C=1NC1=C2C=CC2=C1NC=C2 KRUYGAKMSWKQDA-UHFFFAOYSA-N 0.000 claims description 2
- CIJBLVRHZSSVIC-UHFFFAOYSA-N 8-methyl-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C=1C(C)=CC=C2C=1NC1=C2C=CC2=C1NC=C2 CIJBLVRHZSSVIC-UHFFFAOYSA-N 0.000 claims description 2
- UCZBSVKFYCHQCO-UHFFFAOYSA-N 9-(trifluoromethyl)-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C12=CC=C3C=CNC3=C2NC2=C1C=CC=C2C(F)(F)F UCZBSVKFYCHQCO-UHFFFAOYSA-N 0.000 claims description 2
- FAGACQPJKMSVTQ-UHFFFAOYSA-N 9-ethyl-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound CCC1=CC=CC2=C1NC1=C2C=CC2=C1NC=C2 FAGACQPJKMSVTQ-UHFFFAOYSA-N 0.000 claims description 2
- OHGZLODAKBVSHS-UHFFFAOYSA-N 9-fluoro-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C12=CC=C3C=CNC3=C2NC2=C1C=CC=C2F OHGZLODAKBVSHS-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- MVSOOVKNFXYVRW-UHFFFAOYSA-M OCC[N+](C)(C)C.[Cl-].[Zn] Chemical compound OCC[N+](C)(C)C.[Cl-].[Zn] MVSOOVKNFXYVRW-UHFFFAOYSA-M 0.000 claims description 2
- ZORRHJXCCLMGHU-UHFFFAOYSA-N ethyl 2-(1,10-dihydropyrrolo[2,3-a]carbazol-3-yl)-2-oxoacetate Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1C(=O)C(=O)OCC ZORRHJXCCLMGHU-UHFFFAOYSA-N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- LXOWHRBUEBSILH-UHFFFAOYSA-N methyl 2-(1,10-dihydropyrrolo[2,3-a]carbazol-3-yl)-2-oxoacetate Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1C(=O)C(=O)OC LXOWHRBUEBSILH-UHFFFAOYSA-N 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- MXZKCOUOYWSEKW-UHFFFAOYSA-N 1,10-dihydropyrrolo[2,3-a]carbazole-3-carboxamide Chemical compound C12=CC=CC=C2NC2=C1C=CC1=C2NC=C1C(=O)N MXZKCOUOYWSEKW-UHFFFAOYSA-N 0.000 claims 3
- VMYHTCGHQHXKSV-UHFFFAOYSA-N 2-(1,10-dihydropyrrolo[2,3-a]carbazol-3-yl)-N,N-diethyl-2-hydroxyiminoacetamide Chemical compound CCN(CC)C(=O)C(=NO)c1c[nH]c2c1ccc1c3ccccc3[nH]c21 VMYHTCGHQHXKSV-UHFFFAOYSA-N 0.000 claims 1
- OPYBLXOBBRQZQB-UHFFFAOYSA-N 7-fluoro-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C12=CC(F)=CC=C2NC2=C1C=CC1=C2NC=C1 OPYBLXOBBRQZQB-UHFFFAOYSA-N 0.000 claims 1
- BSTRQWDVQRUDGP-UHFFFAOYSA-N 9-bromo-1,10-dihydropyrrolo[2,3-a]carbazole Chemical compound C12=CC=C3C=CNC3=C2NC2=C1C=CC=C2Br BSTRQWDVQRUDGP-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 14
- 108010083755 proto-oncogene proteins pim Proteins 0.000 abstract description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 174
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 80
- 238000005481 NMR spectroscopy Methods 0.000 description 67
- 239000007787 solid Substances 0.000 description 66
- 238000001819 mass spectrum Methods 0.000 description 52
- 238000002844 melting Methods 0.000 description 50
- 230000008018 melting Effects 0.000 description 50
- 229910003827 NRaRb Inorganic materials 0.000 description 44
- 238000005160 1H NMR spectroscopy Methods 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 23
- 238000004587 chromatography analysis Methods 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- 108091000080 Phosphotransferase Proteins 0.000 description 21
- 102000020233 phosphotransferase Human genes 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229940124639 Selective inhibitor Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- OWWVHLWJKVVCTP-UHFFFAOYSA-N 1-(benzenesulfonyl)-5,6-dihydro-4h-indol-7-one Chemical compound C1=2C(=O)CCCC=2C=CN1S(=O)(=O)C1=CC=CC=C1 OWWVHLWJKVVCTP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000004555 carbazol-3-yl group Chemical group C1=CC(=CC=2C3=CC=CC=C3NC12)* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PPPXRIUHKCOOMU-UHFFFAOYSA-N 1-(benzenesulfonyl)pyrrole Chemical compound C1=CC=CN1S(=O)(=O)C1=CC=CC=C1 PPPXRIUHKCOOMU-UHFFFAOYSA-N 0.000 description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 2
- DAQVEWBELJFYBE-UHFFFAOYSA-N 9h-carbazole-3-carboxamide Chemical compound C1=CC=C2C3=CC(C(=O)N)=CC=C3NC2=C1 DAQVEWBELJFYBE-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- 239000005441 aurora Substances 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- PHCYUJRYSFMJMG-UHFFFAOYSA-N (2-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=CC=C1Br PHCYUJRYSFMJMG-UHFFFAOYSA-N 0.000 description 1
- HBHPTOKYVGZBAJ-UHFFFAOYSA-N (2-ethylanilino)azanium;chloride Chemical compound Cl.CCC1=CC=CC=C1NN HBHPTOKYVGZBAJ-UHFFFAOYSA-N 0.000 description 1
- VFZYLSYYMHFPSY-UHFFFAOYSA-N (2-fluoroanilino)azanium;chloride Chemical compound Cl.NNC1=CC=CC=C1F VFZYLSYYMHFPSY-UHFFFAOYSA-N 0.000 description 1
- BDXZOJVMTJOAPS-UHFFFAOYSA-N (3,5-dichlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC(Cl)=CC(Cl)=C1 BDXZOJVMTJOAPS-UHFFFAOYSA-N 0.000 description 1
- RPYIPFXHIKXRKS-UHFFFAOYSA-N (3-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=CC(Br)=C1 RPYIPFXHIKXRKS-UHFFFAOYSA-N 0.000 description 1
- GPTOGZLZMLJZCV-UHFFFAOYSA-N (3-methylphenyl)hydrazine Chemical compound CC1=CC=CC(NN)=C1 GPTOGZLZMLJZCV-UHFFFAOYSA-N 0.000 description 1
- RGGOWBBBHWTTRE-UHFFFAOYSA-N (4-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Br)C=C1 RGGOWBBBHWTTRE-UHFFFAOYSA-N 0.000 description 1
- FEKUXLUOKFSMRO-UHFFFAOYSA-N (4-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(F)C=C1 FEKUXLUOKFSMRO-UHFFFAOYSA-N 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- UXDLLFIRCVPPQP-UHFFFAOYSA-N 4-hydrazinylbenzonitrile;hydrochloride Chemical compound [Cl-].[NH3+]NC1=CC=C(C#N)C=C1 UXDLLFIRCVPPQP-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000002272 Annona cherimola Nutrition 0.000 description 1
- 235000005288 Annona lutescens Nutrition 0.000 description 1
- 235000005274 Annona squamosa Nutrition 0.000 description 1
- 244000028821 Annona squamosa Species 0.000 description 1
- 102000043139 CK2 family Human genes 0.000 description 1
- 108091054872 CK2 family Proteins 0.000 description 1
- 102100033086 Calcium/calmodulin-dependent protein kinase type 1 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101710118321 Casein kinase I isoform alpha Proteins 0.000 description 1
- 102100034356 Casein kinase I isoform alpha-like Human genes 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 238000006641 Fischer synthesis reaction Methods 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 description 1
- 102100032826 Homeodomain-interacting protein kinase 3 Human genes 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000944250 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1 Proteins 0.000 description 1
- 101001014196 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 101001066401 Homo sapiens Homeodomain-interacting protein kinase 2 Proteins 0.000 description 1
- 101001066389 Homo sapiens Homeodomain-interacting protein kinase 3 Proteins 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- 101001059429 Homo sapiens MAP/microtubule affinity-regulating kinase 3 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 description 1
- 101000976899 Homo sapiens Mitogen-activated protein kinase 15 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000945272 Homo sapiens Phosphorylase b kinase regulatory subunit alpha, liver isoform Proteins 0.000 description 1
- 101001074444 Homo sapiens Polycystin-1 Proteins 0.000 description 1
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 1
- 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 description 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 1
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 1
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 101000794043 Homo sapiens Serine/threonine-protein kinase BRSK2 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 1
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 1
- 101000588545 Homo sapiens Serine/threonine-protein kinase Nek7 Proteins 0.000 description 1
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
- 101000987295 Homo sapiens Serine/threonine-protein kinase PAK 5 Proteins 0.000 description 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 101150057269 IKBKB gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101150028321 Lck gene Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 description 1
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
- 101710141393 MAP kinase-activated protein kinase 3 Proteins 0.000 description 1
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 102100028920 MAP/microtubule affinity-regulating kinase 3 Human genes 0.000 description 1
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 description 1
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 description 1
- 102100023483 Mitogen-activated protein kinase 15 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 101150020891 PRKCA gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100033548 Phosphorylase b kinase regulatory subunit alpha, liver isoform Human genes 0.000 description 1
- 229940122016 Pim kinase inhibitor Drugs 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 description 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 1
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 1
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 1
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 102100029891 Serine/threonine-protein kinase BRSK2 Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 1
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 1
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 description 1
- 102100031400 Serine/threonine-protein kinase Nek7 Human genes 0.000 description 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical compound [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- PCLHDMUPSIFJKW-UHFFFAOYSA-L [Cl-].OCC[N+](C)(C)C.[Cl-].[Zn+] Chemical compound [Cl-].OCC[N+](C)(C)C.[Cl-].[Zn+] PCLHDMUPSIFJKW-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- ZWWXDCOPVYATOQ-UHFFFAOYSA-N amino-(4-nitrophenyl)azanium;chloride Chemical compound [Cl-].N[NH2+]C1=CC=C([N+]([O-])=O)C=C1 ZWWXDCOPVYATOQ-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 150000001716 carbazoles Chemical class 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000004942 imidazo[1,2-b]pyridazines Chemical class 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LZNLYVWOSKOHPZ-UHFFFAOYSA-N n,n-diethyl-2-oxoacetamide Chemical compound CCN(CC)C(=O)C=O LZNLYVWOSKOHPZ-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical class Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- YSVQLWJDHYBITL-UHFFFAOYSA-N ppse Chemical compound C[Si](C)(C)OP(=O)=O YSVQLWJDHYBITL-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229920000685 trimethylsilyl polyphosphate Polymers 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0803752A FR2933409B1 (fr) | 2008-07-03 | 2008-07-03 | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
| FR0803752 | 2008-07-03 | ||
| PCT/FR2009/000788 WO2010000978A1 (fr) | 2008-07-03 | 2009-06-25 | NOUVEAUX PYRROLO [2,3-a] CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2729690A1 true CA2729690A1 (fr) | 2010-01-07 |
Family
ID=40328682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2729690A Abandoned CA2729690A1 (fr) | 2008-07-03 | 2009-06-25 | Nouveaux pyrrolo [2,3-a] carbazoles et leur utilisation comme inhibiteurs des kinases pim |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8481586B2 (https=) |
| EP (1) | EP2326649B1 (https=) |
| JP (1) | JP5663476B2 (https=) |
| AT (1) | ATE551344T1 (https=) |
| CA (1) | CA2729690A1 (https=) |
| FR (1) | FR2933409B1 (https=) |
| WO (1) | WO2010000978A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| SI2432472T1 (sl) | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| KR101488565B1 (ko) | 2011-12-07 | 2015-02-03 | 주식회사 두산 | 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자 |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| KR101452579B1 (ko) * | 2012-08-17 | 2014-10-21 | 주식회사 두산 | 신규 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| KR101537436B1 (ko) | 2012-08-17 | 2015-07-17 | 주식회사 두산 | 신규 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| FR3001219A1 (fr) * | 2013-01-22 | 2014-07-25 | Centre Nat Rech Scient | Inhibiteurs de kinases |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| KR20260008165A (ko) | 2019-02-12 | 2026-01-15 | 스미토모 파마 아메리카, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN120302975A (zh) | 2022-10-31 | 2025-07-11 | 住友制药美国公司 | 治疗骨髓增生性肿瘤的pim1抑制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057979A1 (es) * | 2005-10-06 | 2008-01-09 | Schering Corp | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. |
| US20070117804A1 (en) * | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
-
2008
- 2008-07-03 FR FR0803752A patent/FR2933409B1/fr not_active Expired - Fee Related
-
2009
- 2009-06-25 JP JP2011515526A patent/JP5663476B2/ja not_active Expired - Fee Related
- 2009-06-25 WO PCT/FR2009/000788 patent/WO2010000978A1/fr not_active Ceased
- 2009-06-25 US US13/002,423 patent/US8481586B2/en not_active Expired - Fee Related
- 2009-06-25 EP EP09772661A patent/EP2326649B1/fr not_active Not-in-force
- 2009-06-25 CA CA2729690A patent/CA2729690A1/fr not_active Abandoned
- 2009-06-25 AT AT09772661T patent/ATE551344T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| ATE551344T1 (de) | 2012-04-15 |
| FR2933409B1 (fr) | 2010-08-27 |
| US8481586B2 (en) | 2013-07-09 |
| EP2326649B1 (fr) | 2012-03-28 |
| EP2326649A1 (fr) | 2011-06-01 |
| WO2010000978A1 (fr) | 2010-01-07 |
| JP5663476B2 (ja) | 2015-02-04 |
| JP2011526610A (ja) | 2011-10-13 |
| US20110263669A1 (en) | 2011-10-27 |
| FR2933409A1 (fr) | 2010-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2729690A1 (fr) | Nouveaux pyrrolo [2,3-a] carbazoles et leur utilisation comme inhibiteurs des kinases pim | |
| JP7148709B2 (ja) | バニン阻害剤としてのヘテロ芳香族化合物 | |
| FR3000492A1 (fr) | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases | |
| CA2678007A1 (fr) | Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations | |
| EP0737685A1 (fr) | Nouveaux composés pyridiniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
| EA008666B1 (ru) | Модифицированная реакция пикте-шпенглера и полученные с ее использованием продукты | |
| FR3000493A1 (fr) | Nouveaux inhibiteurs de proteines kinases | |
| FR2959510A1 (fr) | Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques | |
| JP2004501919A (ja) | 化学化合物 | |
| CA2766909A1 (fr) | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one,leur preparation et leur utilisation pharmaceutique | |
| KR20260028873A (ko) | Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체 | |
| El‐Sharkawy et al. | Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors | |
| TW201103905A (en) | 5-alkynyl-pyridines | |
| FR2943057A1 (fr) | DERIVES DE 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO°2,1-a!ISOINDOL-6(10bH)- ONES, LEUR PROCEDE DE PREPARATION ET LEURS UTILISATIONS THERAPEUTIQUES | |
| CA2896209A1 (fr) | 3,5-diaryl-azaindoles comme inhibiteurs de la proteine dyrk1a pour le traitement des deficiences cognitives liees au syndrome de down et a la maladie d'alzheimer | |
| TW201632526A (zh) | 免疫疾病之預防及／或治療劑 | |
| HRP920897A2 (hr) | Spojevi indenoindola i postupak za njihovo dobivanje | |
| Servín‐García et al. | Late‐stage functionalization of Vouacapane derivatives from Caesalpinia platyloba by a Groebke− Blackburn− Bienaymé reaction | |
| CA2602303A1 (en) | Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents | |
| CA2771189C (fr) | Nouveaux derives dihydro-oxazolobenzodiazepinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| Pawar et al. | Palladium Catalyzed Tricyclohexylphosphine Ligand Associated Synthesis of N‐(2‐(pyridine‐4‐yl)‐1H‐pyrrolo [3, 2‐c]‐pyridin‐6‐yl‐(substituted)‐sulfonamide Derivatives as Antiproliferative Agents | |
| Duda et al. | Intramolecular Oxidative Diaryl Coupling of Tetrasubstituted Diphenylamines for the Preparation of Bis (trifluoromethyl) Dimethyl Carbazoles | |
| Giurinia et al. | Intramolecular Oxidative Diaryl Coupling of Tetrasubstituted Diphenylamines for the Preparation of Bis (trifluoromethyl) Dimethyl Carbazoles | |
| WO2026017148A1 (zh) | 一种malt1抑制剂及其制备方法和用途 | |
| CA2580203A1 (en) | Tricycles, their manufacture and use as pharmaceutical agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140526 |
|
| FZDE | Discontinued |
Effective date: 20161123 |